The drug solidifies its place as a first-line treatment option in AML.
Gabriela Aponte-Melendez, PharmD
Advertisement
Articles by Gabriela Aponte-Melendez, PharmD
The program develops patient-centered oncology pharmacists through comprehensive training.
Advancements include novel combination therapies and improved diagnostic techniques.
Multiple P13K inhibitors have showed promise in treating genetically-mutated forms of breast cancer.
Advertisement
Latest Updated Articles
Shaping the Future of Oncology Pharmacy Through the NCODA Medically Integrated Oncology Pharmacy Residency ProgramPublished: December 27th 2024 | Updated:
Quizartinib in FLT3-ITD–Positive Acute Myeloid Leukemia: A New Era in Targeted TherapyPublished: February 25th 2025 | Updated:
The Evolution of PI3K Inhibitors in the Treatment of Breast CancerPublished: October 22nd 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
FDA Initiates Approval of Leucovorin for Patients With Cerebral Folate Deficiency
2
Rapid CAR T Expansion Linked to Delayed Neurotoxicity in Patients Treated With Cilta-Cel
3
Hercessi, Biosimilar to Herceptin, Shows Favorable Efficacy, Safety in Treating HER2+ MBC in Real-World Setting
4
IMS: Shaping the Future of Multiple Myeloma with Anti-CD38 Quadruplets
5
